| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.66(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.29 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
783,093 |
1,200,396 |
1,364,804 |
2,016,775 |
| Total Sell Value |
$6,638,135 |
$9,405,600 |
$10,045,164 |
$10,779,551 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
19 |
36 |
61 |
106 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Grammer Elizabeth A |
SVP, General Counsel |
• – – |
2016-09-23 |
4 |
OE |
$1.08 |
$9,695 |
D/D |
3,560 |
3,560 |
|
- |
|
| Grammer Elizabeth A |
SVP, General Counsel |
• – – |
2016-09-22 |
4 |
AS |
$12.00 |
$17,280 |
D/D |
(1,440) |
0 |
|
- |
|
| Grammer Elizabeth A |
SVP, General Counsel |
• – – |
2016-09-22 |
4 |
OE |
$1.08 |
$1,555 |
D/D |
1,440 |
1,440 |
|
- |
|
| Grammer Elizabeth A |
SVP, General Counsel |
• – – |
2016-09-19 |
4 |
AS |
$11.21 |
$76,880 |
D/D |
(6,859) |
0 |
|
- |
|
| Grammer Elizabeth A |
SVP, General Counsel |
• – – |
2016-09-19 |
4 |
OE |
$1.08 |
$5,400 |
D/D |
5,000 |
6,859 |
|
- |
|
| Weller Harry R |
10% Owner |
– – • |
2016-07-18 |
4 |
B |
$8.73 |
$13,333,338 |
I/I |
1,527,301 |
2,665,519 |
1.5 |
- |
|
| Viswanathan Ravi |
10% Owner |
– – • |
2016-07-18 |
4 |
B |
$8.73 |
$13,333,338 |
I/I |
1,527,301 |
2,665,519 |
1.5 |
- |
|
| Mott David M |
Director |
– • • |
2016-07-18 |
4 |
B |
$8.73 |
$13,333,338 |
I/I |
1,527,301 |
2,665,519 |
2.25 |
- |
|
| Sakoda Jon |
10% Owner |
– – • |
2016-07-18 |
4 |
B |
$8.73 |
$13,333,338 |
I/I |
1,527,301 |
2,665,519 |
1.5 |
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2016-07-18 |
4 |
B |
$8.73 |
$20,000,002 |
I/I |
2,290,951 |
2,665,519 |
1.5 |
- |
|
| Kolluri Krishna Kittu |
10% Owner |
– – • |
2016-07-18 |
4 |
B |
$8.73 |
$20,000,002 |
I/I |
2,290,951 |
2,665,519 |
1.5 |
- |
|
| Makower Joshua |
10% Owner |
– – • |
2016-07-18 |
4 |
B |
$8.73 |
$13,333,338 |
I/I |
1,527,301 |
2,665,519 |
1.5 |
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2016-07-18 |
4 |
B |
$8.73 |
$13,333,338 |
I/I |
1,527,301 |
2,665,519 |
1.5 |
- |
|
| Barrett M James |
10% Owner |
– – • |
2016-07-18 |
4 |
B |
$8.73 |
$6,666,665 |
I/I |
763,650 |
8,752,543 |
1.5 |
- |
|
| Nea 12 Gp, Llc |
10% Owner |
– – • |
2016-07-18 |
4 |
B |
$8.73 |
$6,666,665 |
D/D |
763,650 |
8,752,543 |
2.45 |
- |
|
| Barris Peter J |
10% Owner |
– – • |
2016-07-18 |
4 |
B |
$8.73 |
$20,000,002 |
I/I |
2,290,951 |
2,665,519 |
1.5 |
- |
|
| Baskett Forest |
10% Owner |
– – • |
2016-07-18 |
4 |
B |
$8.73 |
$20,000,002 |
I/I |
2,290,951 |
2,665,519 |
1.5 |
- |
|
| Nea 15 Gp, Llc |
10% Owner |
– – • |
2016-07-18 |
4 |
B |
$8.73 |
$13,333,338 |
I/I |
1,527,301 |
2,665,519 |
1.5 |
- |
|
| Mott David M |
Director |
– • • |
2016-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
8,522 |
14,343 |
|
- |
|
| Bertrand William C Jr |
Director |
– • – |
2016-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
4,854 |
9,854 |
|
- |
|
| Rodgers Richard J |
Director |
– • – |
2016-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
6,742 |
11,296 |
|
- |
|
| Ringold Gordon |
Director |
– • – |
2016-03-21 |
4 |
B |
$7.77 |
$116,540 |
I/I |
15,000 |
15,000 |
2.1 |
- |
|
| Rosenbaum David P. |
SVP, Drug Development |
• – – |
2016-03-03 |
4 |
AS |
$10.74 |
$12,110 |
D/D |
(1,128) |
22,144 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2016-02-16 |
4 |
AS |
$10.25 |
$51,272 |
D/D |
(5,000) |
1,282 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2016-02-16 |
4 |
OE |
$0.54 |
$2,700 |
D/D |
5,000 |
6,282 |
|
- |
|
559 Records found
|
|
Page 17 of 23 |
|
|
0.26 (3.78%) 
